Results of allogeneic stem cell transplantation with nonmyeloablative regimens for CLL
Study . | No. patients . | NRM, % (follow-up time, y) . | Conditioning regimen . | Patients with related donor, % . | PFS, % (year of projection) . | OS, % (year of projection) . |
|---|---|---|---|---|---|---|
| Dreger et al (EBMT, 2003)90 | 77 | 18 (1) | Several | 82 | 56 (2) | 72 (2) |
| Schetelig et al (2003)91 | 30 | 15 (2) | Fluda + Bu + ATG | 50 | 67 (2) | 72 (2) |
| Khouri et al (2004)92 | 17 | 22 (2) | Fluda + Cy ± Rituximab | 100 | 60 (2) | 80 (2) |
| Sorror et al (2005)93 | 64 | 22 (2) | Fluda ± TBI (2 Gy) | 69 | 52 (2) | 60 (2) |
Study . | No. patients . | NRM, % (follow-up time, y) . | Conditioning regimen . | Patients with related donor, % . | PFS, % (year of projection) . | OS, % (year of projection) . |
|---|---|---|---|---|---|---|
| Dreger et al (EBMT, 2003)90 | 77 | 18 (1) | Several | 82 | 56 (2) | 72 (2) |
| Schetelig et al (2003)91 | 30 | 15 (2) | Fluda + Bu + ATG | 50 | 67 (2) | 72 (2) |
| Khouri et al (2004)92 | 17 | 22 (2) | Fluda + Cy ± Rituximab | 100 | 60 (2) | 80 (2) |
| Sorror et al (2005)93 | 64 | 22 (2) | Fluda ± TBI (2 Gy) | 69 | 52 (2) | 60 (2) |
NRM indicates nonrelapse mortality; PFS, progression-free survival; OS, overall survival; Fluda, fludarabine; Bu, busulfan; ATG, antithymocyte globulin; and Cy, cyclophosphamide.